ID   CMTR1_HUMAN             Reviewed;         835 AA.
AC   Q8N1G2; A8K949; Q14670; Q96FJ9;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   10-MAY-2017, entry version 124.
DE   RecName: Full=Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1;
DE            EC=2.1.1.57 {ECO:0000269|PubMed:21310715};
DE   AltName: Full=Cap methyltransferase 1;
DE   AltName: Full=Cap1 2'O-ribose methyltransferase 1;
DE            Short=MTr1;
DE            Short=hMTr1;
DE   AltName: Full=FtsJ methyltransferase domain-containing protein 2;
DE   AltName: Full=Interferon-stimulated gene 95 kDa protein;
DE            Short=ISG95;
GN   Name=CMTR1; Synonyms=FTSJD2, KIAA0082, MTR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7788527; DOI=10.1093/dnares/2.1.37;
RA   Nagase T., Miyajima N., Tanaka A., Sazuka T., Seki N., Sato S.,
RA   Tabata S., Ishikawa K., Kawarabayasi Y., Kotani H., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. III.
RT   The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:37-43(1995).
RN   [2]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INDUCTION BY INTERFERONS ALPHA AND BETA.
RX   PubMed=12743294; DOI=10.1128/JVI.77.11.6367-6375.2003;
RA   Geiss G.K., Carter V.S., He Y., Kwieciszewski B.K., Holzman T.,
RA   Korth M.J., Lazaro C.A., Fausto N., Bumgarner R.E., Katze M.G.;
RT   "Gene expression profiling of the cellular transcriptional network
RT   regulated by alpha/beta interferon and its partial attenuation by the
RT   hepatitis C virus nonstructural 5A protein.";
RL   J. Virol. 77:6367-6375(2003).
RN   [7]
RP   INDUCTION BY VIRAL INFECTION.
RX   PubMed=12743306; DOI=10.1128/JVI.77.11.6493-6506.2003;
RA   Guerra S., Lopez-Fernandez L.A., Pascual-Montano A., Munoz M.,
RA   Harshman K., Esteban M.;
RT   "Cellular gene expression survey of vaccinia virus infection of human
RT   HeLa cells.";
RL   J. Virol. 77:6493-6506(2003).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   FUNCTION, INTERACTION WITH POLR2A, SUBCELLULAR LOCATION, AND
RP   INDUCTION.
RX   PubMed=18533109; DOI=10.1016/j.bbrc.2008.05.137;
RA   Haline-Vaz T., Silva T.C.L., Zanchin N.I.T.;
RT   "The human interferon-regulated ISG95 protein interacts with RNA
RT   polymerase II and shows methyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 372:719-724(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-108, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=20713356; DOI=10.1074/jbc.M110.155283;
RA   Belanger F., Stepinski J., Darzynkiewicz E., Pelletier J.;
RT   "Characterization of hMTr1, a human Cap1 2'-O-Ribose
RT   methyltransferase.";
RL   J. Biol. Chem. 285:33037-33044(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF LYS-239; ASP-364 AND LYS-404.
RX   PubMed=21310715; DOI=10.1093/nar/gkr038;
RA   Werner M., Purta E., Kaminska K.H., Cymerman I.A., Campbell D.A.,
RA   Mittra B., Zamudio J.R., Sturm N.R., Jaworski J., Bujnicki J.M.;
RT   "2'-O-ribose methylation of cap2 in human: function and evolution in a
RT   horizontally mobile family.";
RL   Nucleic Acids Res. 39:4756-4768(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-66 AND SER-91, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-53, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 126-550 IN COMPLEX WITH
RP   S-ADENOSYL-L-METHIONINE AND A CAPPED OLIGORIBONUCLEOTIDE SUBSTRATE,
RP   AND MUTAGENESIS OF LYS-203 AND ARG-228.
RX   PubMed=24402442; DOI=10.1038/ncomms4004;
RA   Smietanski M., Werner M., Purta E., Kaminska K.H., Stepinski J.,
RA   Darzynkiewicz E., Nowotny M., Bujnicki J.M.;
RT   "Structural analysis of human 2'-O-ribose methyltransferases involved
RT   in mRNA cap structure formation.";
RL   Nat. Commun. 5:3004-3004(2014).
CC   -!- FUNCTION: S-adenosyl-L-methionine-dependent methyltransferase that
CC       mediates mRNA cap1 2'-O-ribose methylation to the 5'-cap structure
CC       of mRNAs. Methylates the ribose of the first nucleotide of a
CC       m(7)GpppG-capped mRNA and small nuclear RNA (snRNA) to produce
CC       m(7)GpppRm (cap1). Displays a preference for cap0 transcripts.
CC       Cap1 modification is linked to higher levels of translation. May
CC       be involved in the interferon response pathway.
CC       {ECO:0000269|PubMed:18533109, ECO:0000269|PubMed:20713356,
CC       ECO:0000269|PubMed:21310715}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + a 5'-(N(7)-methyl
CC       5'-triphosphoguanosine)-(purine-ribonucleotide)-[mRNA] = S-
CC       adenosyl-L-homocysteine + a 5'-(N(7)-methyl 5'-
CC       triphosphoguanosine)-(2'-O-methyl-purine-ribonucleotide)-[mRNA].
CC       {ECO:0000269|PubMed:21310715}.
CC   -!- SUBUNIT: Interacts with POLR2A (via C-terminus).
CC       {ECO:0000269|PubMed:18533109}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:18533109,
CC       ECO:0000269|PubMed:21310715}.
CC   -!- INDUCTION: By interferons alpha and beta, and by Vaccinia virus
CC       infection. {ECO:0000269|PubMed:12743294,
CC       ECO:0000269|PubMed:12743306, ECO:0000269|PubMed:18533109}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA07893.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D43949; BAA07893.2; ALT_INIT; mRNA.
DR   EMBL; AK292564; BAF85253.1; -; mRNA.
DR   EMBL; AL353597; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010731; AAH10731.2; -; mRNA.
DR   EMBL; BC031890; AAH31890.1; -; mRNA.
DR   CCDS; CCDS4835.1; -.
DR   RefSeq; NP_055865.1; NM_015050.2.
DR   UniGene; Hs.520102; -.
DR   PDB; 4N48; X-ray; 2.70 A; A/B=126-550.
DR   PDB; 4N49; X-ray; 1.90 A; A=126-550.
DR   PDB; 4N4A; X-ray; 2.35 A; A=126-550.
DR   PDBsum; 4N48; -.
DR   PDBsum; 4N49; -.
DR   PDBsum; 4N4A; -.
DR   ProteinModelPortal; Q8N1G2; -.
DR   SMR; Q8N1G2; -.
DR   BioGrid; 116703; 14.
DR   IntAct; Q8N1G2; 4.
DR   STRING; 9606.ENSP00000362550; -.
DR   iPTMnet; Q8N1G2; -.
DR   PhosphoSitePlus; Q8N1G2; -.
DR   BioMuta; CMTR1; -.
DR   DMDM; 74750894; -.
DR   EPD; Q8N1G2; -.
DR   MaxQB; Q8N1G2; -.
DR   PaxDb; Q8N1G2; -.
DR   PeptideAtlas; Q8N1G2; -.
DR   PRIDE; Q8N1G2; -.
DR   TopDownProteomics; Q8N1G2; -.
DR   Ensembl; ENST00000373451; ENSP00000362550; ENSG00000137200.
DR   GeneID; 23070; -.
DR   KEGG; hsa:23070; -.
DR   UCSC; uc003ons.4; human.
DR   CTD; 23070; -.
DR   DisGeNET; 23070; -.
DR   GeneCards; CMTR1; -.
DR   HGNC; HGNC:21077; CMTR1.
DR   HPA; HPA029954; -.
DR   HPA; HPA029979; -.
DR   HPA; HPA029980; -.
DR   MIM; 616189; gene.
DR   neXtProt; NX_Q8N1G2; -.
DR   OpenTargets; ENSG00000137200; -.
DR   PharmGKB; PA162389052; -.
DR   eggNOG; KOG3673; Eukaryota.
DR   eggNOG; ENOG410XP08; LUCA.
DR   GeneTree; ENSGT00530000063742; -.
DR   HOGENOM; HOG000021970; -.
DR   HOVERGEN; HBG057271; -.
DR   KO; K14589; -.
DR   OMA; SRLFWEW; -.
DR   OrthoDB; EOG091G02K5; -.
DR   PhylomeDB; Q8N1G2; -.
DR   TreeFam; TF314897; -.
DR   BioCyc; MetaCyc:ENSG00000137200-MONOMER; -.
DR   GenomeRNAi; 23070; -.
DR   PRO; PR:Q8N1G2; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000137200; -.
DR   CleanEx; HS_FTSJD2; -.
DR   ExpressionAtlas; Q8N1G2; baseline and differential.
DR   Genevisible; Q8N1G2; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004483; F:mRNA (nucleoside-2'-O-)-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0006370; P:7-methylguanosine mRNA capping; IDA:UniProtKB.
DR   GO; GO:0097309; P:cap1 mRNA methylation; IDA:UniProtKB.
DR   GO; GO:0080009; P:mRNA methylation; IDA:UniProtKB.
DR   InterPro; IPR030376; Cap_mRNA_MeTrfase_1.
DR   InterPro; IPR000467; G_patch_dom.
DR   InterPro; IPR025816; RrmJ-type_MeTrfase.
DR   InterPro; IPR002877; rRNA_MeTrfase_FtsJ_dom.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   InterPro; IPR001202; WW_dom.
DR   PANTHER; PTHR16121:SF3; PTHR16121:SF3; 1.
DR   Pfam; PF01728; FtsJ; 1.
DR   Pfam; PF01585; G-patch; 1.
DR   SMART; SM00443; G_patch; 1.
DR   SMART; SM00456; WW; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS50174; G_PATCH; 1.
DR   PROSITE; PS51613; SAM_MT_RRMJ; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Methyltransferase;
KW   mRNA capping; mRNA processing; Nucleus; Phosphoprotein;
KW   Reference proteome; S-adenosyl-L-methionine; Transferase.
FT   CHAIN         1    835       Cap-specific mRNA (nucleoside-2'-O-)-
FT                                methyltransferase 1.
FT                                /FTId=PRO_0000251239.
FT   DOMAIN       87    133       G-patch. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00092}.
FT   DOMAIN      231    450       RrmJ-type SAM-dependent 2'-O-MTase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00945}.
FT   DOMAIN      752    786       WW. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   REGION      203    207       Substrate binding. {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   REGION      277    283       S-adenosyl-L-methionine binding.
FT                                {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   REGION      335    336       S-adenosyl-L-methionine binding.
FT                                {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   REGION      374    376       Substrate binding. {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   REGION      727    835       Interaction with POLR2A.
FT                                {ECO:0000269|PubMed:18533109}.
FT   MOTIF         2     19       Bipartite nuclear localization signal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00768,
FT                                ECO:0000305|PubMed:24402442}.
FT   ACT_SITE    239    239       {ECO:0000305|PubMed:21310715}.
FT   ACT_SITE    364    364       {ECO:0000305|PubMed:21310715}.
FT   ACT_SITE    404    404       Proton acceptor.
FT                                {ECO:0000305|PubMed:21310715}.
FT   BINDING     218    218       Substrate. {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   BINDING     234    234       S-adenosyl-L-methionine.
FT                                {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   BINDING     439    439       Substrate. {ECO:0000244|PDB:4N48,
FT                                ECO:0000244|PDB:4N49,
FT                                ECO:0000269|PubMed:24402442}.
FT   MOD_RES      28     28       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9DBC3}.
FT   MOD_RES      31     31       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9DBC3}.
FT   MOD_RES      53     53       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      66     66       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      91     91       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MUTAGEN     203    203       K->A: Reduces both mRNA cap binding and
FT                                catalytic activity of the enzyme.
FT                                {ECO:0000269|PubMed:24402442}.
FT   MUTAGEN     228    228       R->A: No effect.
FT                                {ECO:0000269|PubMed:24402442}.
FT   MUTAGEN     239    239       K->A: Abolishes catalytic activity.
FT                                {ECO:0000269|PubMed:21310715}.
FT   MUTAGEN     364    364       D->A: Abolishes catalytic activity.
FT                                {ECO:0000269|PubMed:21310715}.
FT   MUTAGEN     404    404       K->A: Abolishes catalytic activity.
FT                                {ECO:0000269|PubMed:21310715}.
FT   CONFLICT    795    795       Y -> H (in Ref. 3; BAF85253).
FT                                {ECO:0000305}.
FT   STRAND      143    146       {ECO:0000244|PDB:4N4A}.
FT   TURN        168    174       {ECO:0000244|PDB:4N49}.
FT   STRAND      176    179       {ECO:0000244|PDB:4N49}.
FT   HELIX       184    186       {ECO:0000244|PDB:4N4A}.
FT   STRAND      189    191       {ECO:0000244|PDB:4N48}.
FT   HELIX       193    204       {ECO:0000244|PDB:4N49}.
FT   HELIX       205    208       {ECO:0000244|PDB:4N49}.
FT   HELIX       211    221       {ECO:0000244|PDB:4N49}.
FT   HELIX       225    227       {ECO:0000244|PDB:4N49}.
FT   TURN        228    231       {ECO:0000244|PDB:4N49}.
FT   STRAND      232    234       {ECO:0000244|PDB:4N49}.
FT   HELIX       235    246       {ECO:0000244|PDB:4N49}.
FT   TURN        247    252       {ECO:0000244|PDB:4N49}.
FT   HELIX       265    267       {ECO:0000244|PDB:4N49}.
FT   STRAND      271    277       {ECO:0000244|PDB:4N49}.
FT   HELIX       282    291       {ECO:0000244|PDB:4N49}.
FT   STRAND      293    300       {ECO:0000244|PDB:4N49}.
FT   HELIX       310    312       {ECO:0000244|PDB:4N49}.
FT   TURN        313    316       {ECO:0000244|PDB:4N4A}.
FT   TURN        318    320       {ECO:0000244|PDB:4N4A}.
FT   STRAND      321    323       {ECO:0000244|PDB:4N4A}.
FT   STRAND      326    328       {ECO:0000244|PDB:4N49}.
FT   HELIX       329    331       {ECO:0000244|PDB:4N48}.
FT   HELIX       339    351       {ECO:0000244|PDB:4N49}.
FT   TURN        352    355       {ECO:0000244|PDB:4N49}.
FT   STRAND      358    363       {ECO:0000244|PDB:4N49}.
FT   TURN        370    372       {ECO:0000244|PDB:4N48}.
FT   HELIX       373    375       {ECO:0000244|PDB:4N49}.
FT   HELIX       376    379       {ECO:0000244|PDB:4N49}.
FT   HELIX       381    394       {ECO:0000244|PDB:4N49}.
FT   STRAND      395    405       {ECO:0000244|PDB:4N49}.
FT   HELIX       411    423       {ECO:0000244|PDB:4N49}.
FT   STRAND      424    430       {ECO:0000244|PDB:4N49}.
FT   STRAND      442    449       {ECO:0000244|PDB:4N49}.
FT   HELIX       454    470       {ECO:0000244|PDB:4N49}.
FT   STRAND      473    481       {ECO:0000244|PDB:4N49}.
FT   HELIX       483    487       {ECO:0000244|PDB:4N49}.
FT   HELIX       490    519       {ECO:0000244|PDB:4N49}.
FT   HELIX       528    539       {ECO:0000244|PDB:4N49}.
SQ   SEQUENCE   835 AA;  95321 MW;  03919512A73C30FB CRC64;
     MKRRTDPECT APIKKQKKRV AELALSLSST SDDEPPSSVS HGAKASTTSL SGSDSETEGK
     QHSSDSFDDA FKADSLVEGT SSRYSMYNSV SQKLMAKMGF REGEGLGKYS QGRKDIVEAS
     SQKGRRGLGL TLRGFDQELN VDWRDEPEPS ACEQVSWFPE CTTEIPDTQE MSDWMVVGKR
     KMIIEDETEF CGEELLHSVL QCKSVFDVLD GEEMRRARTR ANPYEMIRGV FFLNRAAMKM
     ANMDFVFDRM FTNPRDSYGK PLVKDREAEL LYFADVCAGP GGFSEYVLWR KKWHAKGFGM
     TLKGPNDFKL EDFYSASSEL FEPYYGEGGI DGDGDITRPE NISAFRNFVL DNTDRKGVHF
     LMADGGFSVE GQENLQEILS KQLLLCQFLM ALSIVRTGGH FICKTFDLFT PFSVGLVYLL
     YCCFERVCLF KPITSRPANS ERYVVCKGLK VGIDDVRDYL FAVNIKLNQL RNTDSDVNLV
     VPLEVIKGDH EFTDYMIRSN ESHCSLQIKA LAKIHAFVQD TTLSEPRQAE IRKECLRLWG
     IPDQARVAPS SSDPKSKFFE LIQGTEIDIF SYKPTLLTSK TLEKIRPVFD YRCMVSGSEQ
     KFLIGLGKSQ IYTWDGRQSD RWIKLDLKTE LPRDTLLSVE IVHELKGEGK AQRKISAIHI
     LDVLVLNGTD VREQHFNQRI QLAEKFVKAV SKPSRPDMNP IRVKEVYRLE EMEKIFVRLE
     MKIIKGSSGT PKLSYTGRDD RHFVPMGLYI VRTVNEPWTM GFSKSFKKKF FYNKKTKDST
     FDLPADSIAP FHICYYGRLF WEWGDGIRVH DSQKPQDQDK LSKEDVLSFI QMHRA
//
